Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of RANKL inhibition.
Kim AS, Taylor VE, Castro-Martinez A, Dhakal S, Zamerli A, Mohanty ST, Xiao Y, Simic MK, Pantalone A, Chu J, Cheng TL, Croucher PI, Center JR, Girgis CM, McDonald MM.
Kim AS, et al.
J Bone Miner Res. 2025 Jan 23:zjaf008. doi: 10.1093/jbmr/zjaf008. Online ahead of print.
J Bone Miner Res. 2025.
PMID: 39846954